» Articles » PMID: 27864628

Provider Perspectives on Patient-provider Communication for Adjuvant Endocrine Therapy Symptom Management

Overview
Specialties Critical Care
Oncology
Date 2016 Nov 20
PMID 27864628
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Providers' communication skills play a key role in encouraging breast cancer survivors to report symptoms and adhere to long-term treatments such as adjuvant endocrine therapy (AET). The purpose of this study was to examine provider perspectives on patient-provider communication regarding AET symptom management and to explore whether provider perspectives vary across the multi-disciplinary team of providers involved in survivorship care.

Methods: We conducted three one-hour focus groups with a multi-disciplinary group of health care providers including oncology specialists, primary care physicians, and non-physician providers experienced in caring for breast cancer survivors undergoing AET (n = 13). Themes were organized using Epstein and Street's (2007) Framework for Patient-Centered Communication in Cancer Care.

Results: The findings of this study suggest providers' communication behaviors including managing survivors' uncertainty, responding to survivors' emotions, exchanging information, and enabling self-management influences the quality of patient-provider communication about AET symptoms. Additionally, lack of systematic symptom assessment tools for AET requires providers to use discretion in determining which symptoms to discuss with survivors resulting in approaches that vary based on providers' discipline.

Conclusion: There may be AET-specific provider communication skills and behaviors that promote effective patient-provider communication but additional research is needed to identify practices and policies that encourage these skills and behaviors among the many providers involved in survivorship care. Efforts are also needed to coordinate AET symptom assessment across providers, clarify providers' roles in symptom assessment, and determine best practices for AET symptom communication.

Citing Articles

Experiences and management needs of endocrine therapy-related symptoms in patients with breast cancer: a systematic review and qualitative evidence synthesis protocol.

Wang L, Wei T, Liu J, Peng S, Chen J, Hu M BMJ Open. 2023; 13(12):e073915.

PMID: 38149416 PMC: 10711849. DOI: 10.1136/bmjopen-2023-073915.


Silent suffering: the impact of sexual health challenges on patient-clinician communication and adherence to adjuvant endocrine therapy among Black women with early-stage breast cancer.

Anderson J, Paladino A, Blue R, Dangerfield 2nd D, Eggly S, Martin M J Cancer Surviv. 2023; .

PMID: 38114711 PMC: 11216545. DOI: 10.1007/s11764-023-01511-0.


THRIVE intervention development: using participatory action research principles to guide a mHealth app-based intervention to improve oncology care.

Anderson J, Krukowski R, Paladino A, Graff J, Schwartzberg L, Curry A J Hosp Manag Health Policy. 2021; 5.

PMID: 34308256 PMC: 8302021. DOI: 10.21037/jhmhp-20-103.


Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer.

Lambert L, Balneaves L, Howard A, Chia S, Gotay C Curr Oncol. 2021; 28(2):1472-1482.

PMID: 33918560 PMC: 8167827. DOI: 10.3390/curroncol28020139.


Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.

Sheppard V, Sutton A, Hurtado-de-Mendoza A, He J, Dahman B, Edmonds M Cancer Epidemiol Biomarkers Prev. 2021; 30(4):699-709.

PMID: 33514603 PMC: 8330157. DOI: 10.1158/1055-9965.EPI-20-0604.


References
1.
Osse B, Vernooij-Dassen M, Schade E, de Vree B, van den Muijsenbergh M, Grol R . Problems to discuss with cancer patients in palliative care: a comprehensive approach. Patient Educ Couns. 2002; 47(3):195-204. DOI: 10.1016/s0738-3991(02)00019-8. View

2.
Burstein H, Temin S, Anderson H, Buchholz T, Davidson N, Gelmon K . Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014; 32(21):2255-69. PMC: 4876310. DOI: 10.1200/JCO.2013.54.2258. View

3.
Loprinzi C, Kugler J, Sloan J, Mailliard J, Lavasseur B, Barton D . Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2001; 356(9247):2059-63. DOI: 10.1016/S0140-6736(00)03403-6. View

4.
Crew K, Capodice J, Greenlee H, Brafman L, Fuentes D, Awad D . Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol. 2010; 28(7):1154-60. DOI: 10.1200/JCO.2009.23.4708. View

5.
McCowan C, Shearer J, Donnan P, Dewar J, Crilly M, Thompson A . Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008; 99(11):1763-8. PMC: 2600703. DOI: 10.1038/sj.bjc.6604758. View